DelveInsight’s Oral Mucositis Market Insights Report 2032 offers a detailed analysis of the disease, its causes, symptoms, diagnostics modalities, and treatment options.
The Oral Mucositis market report also offers comprehensive insights into Oral Mucositis market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing Oral Mucositis market size growth forward.
Some of the key highlights from the Oral Mucositis Market Insights Report:
In the year 2020, the total Oral Mucositis incident cases were 1,480,453 cases in the 7MM. These cases are expected to grow in the study period 2018–2030.
As per the DelveInsight estimates, in the United States, the total Grade-specific Oral Mucositis incident cases were highest for Grade III, with 209,660 patients in the year 2020. These cases are expected to grow in the study period 2018–2030.
In Germany, the total treated cases of Oral Mucositis were 116,300 in the year 2020. These cases are expected to grow in the study period 2018–2030.
Major players such as Galera Therapeutics, Soligenix, Monopar Therapeutics, NeoMedLight, BrainCool, MuReva (Lumitex), Oncozenge, and others are involved in developing therapies for the treatment and management of Oral Mucositis. These therapies are currently under different stages of development.
Key pipeline therapies in the Oral Mucositis market include Avasopasem (GC4419), SGX942, Validive (Clonidine Lauriad), CareMin650, Cooral/CoolPrevent, MuReva Phototherapy System, BupiZenge, among others.
Oral Mucositis: Overview
Oral mucositis refers to erythematous and ulcerative lesions of the oral mucosa observed in patients with cancer being treated with chemotherapy and with radiation therapy to fields involving the oral cavity. This can lead to several problems, including pain, nutritional problems resulting from the inability to eat, and an increased risk of infection due to open sores in the mucosa. It significantly affects the patient’s quality of life and can be dose-limiting. This condition generally begins 5-10 days following chemotherapy and lasts one week to six weeks.
For more insights into disease, causes, and treatment, contact Oral Mucositis Treatment Landscape.
Oral Mucositis Epidemiology Segmentation
The Oral Mucositis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Oral Mucositis Prevalence
Age-Specific Oral Mucositis Prevalence
Gender-Specific Oral Mucositis Prevalence
Diagnosed and Treatable Cases of Oral Mucositis
Oral Mucositis Market
Oral mucositis has traditionally been treated with palliative care, while focused treatment strategies are currently being developed. Although it is impossible to prevent mucositis from developing, some steps can be taken before starting radiation.
Patients’ compliance and education, hydration, nutritional support, saline rinses, topical and systemic pain medication, and infection surveillance and treatment were all part of the traditional management of oral mucositis.
Palliative therapies such as palifermin and benzydamine have also been utilized in rare circumstances. Oral mucositis caused by cancer treatments is widely recognized as chemotherapy and radiation therapy’s most debilitating side effect.
Oral Mucositis Pipeline Therapies and Key Companies
Avasopasem (GC4419): Galera Therapeutics
Validive (Clonidine Lauriad): Monopar Therapeutics
MuReva Phototherapy System: MuReva (Lumitex)
For more information, visit Oral Mucositis Market Analysis, Patient Pool, and Emerging Therapies.
Oral Mucositis Market Drivers
Rising prevalent population
Scope of the Report
Descriptive overview of Oral Mucositis, covering causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
Comprehensive insight into Oral Mucositis epidemiology and treatment in the 7MM
Current and emerging therapies for Oral Mucositis
Oral Mucositis market drivers and barriers
Table of Contents
Competitive Intelligence Analysis for Oral Mucositis
Oral Mucositis Market Overview at a Glance
Executive Summary of Oral Mucositis
Oral Mucositis Epidemiology and Market Methodology
Oral Mucositis Epidemiology and Patient Population
Oral Mucositis Patient Journey
Treatment Algorithm, Current Treatment, and Medical Practices
Key Endpoints in Oral Mucositis Clinical Trials
Oral Mucositis Marketed Therapies
Oral Mucositis Emerging Therapies
Oral Mucositis: 7 Major Market Analysis
Access and Reimbursement Overview of Oral Mucositis
Oral Mucositis Market Drivers
Oral Mucositis Market Barriers
Learn more about the report offerings @ Oral Mucositis Market Outlook
Oral Mucositis Market
Oral Mucositis Epidemiology
Oral Mucositis Pipeline
Intrahepatic Cholangiocarcinoma (ICCA) Market
COVID 19 Therapeutic Pipeline, Vaccines, and Diagnostics Competitive Landscape, 2020
Cervical Dysplasia Market
Diabetic Kidney Disease Market
Acute Respiratory Distress Syndrome (ARDS) Market
Acute Kidney Injury (AKI) Market
Renal Anemia Market
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States